Expression signature developed from a complex series of mouse models accurately predicts human breast cancer survival

Mei He, David P. Mangiameli, Stefan Kachala, Kent Hunter, John Gillespie, Xiaopeng Bian, H. C Jennifer Shen, Steven K. Libutti

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: The capability of microarray platform to interrogate thousands of genes has led to the development of molecular diagnostic tools for cancer patients. Although large-scale comparative studies on clinical samples are often limited by the access of human tissues, expression profiling databases of various human cancer types are publicly available for researchers. Given that mouse models have been instrumental to our current understanding of cancer progression, we aimed to test the hypothesis that novel gene signatures possessing predictability in clinical outcome can be derived by coupling genomic analyses in mouse models of cancer with publicly available human cancer data sets. Experimental Design: We established a complex series of syngeneic metastatic animal models using a murine breast cancer cell line. Tumor RNA was hybridized on Affymetrix MouseGenome-430A2.0 Gene-Chips. With the use of Venn logic, gene signatures that represent metastatic competency were derived and tested against publicly available human breast and lung cancer data sets. Results: Survival analyses showed that the spontaneous metastasis gene signature was significantly associated with metastasis-free and overall survival (P < 0.0005). Consequently, the six-gene model was determined and showed statistical predictability in predicting survival in breast cancer patients. In addition, the model was able to stratify poor from good prognosis for lung cancer patients in most data sets analyzed. Conclusions: Together, our data support that novel gene signature derived from mouse models of cancer can be used for predicting human cancer outcome. Our approaches set precedence that similar strategies may be used to decipher novel gene signatures for clinical utility.

Original languageEnglish (US)
Pages (from-to)249-259
Number of pages11
JournalClinical Cancer Research
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Breast Neoplasms
Survival
Neoplasms
Genes
Lung Neoplasms
Neoplasm Metastasis
Molecular Pathology
Survival Analysis
Oligonucleotide Array Sequence Analysis
Research Design
Animal Models
Research Personnel
Databases
RNA
Cell Line
Datasets

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

He, M., Mangiameli, D. P., Kachala, S., Hunter, K., Gillespie, J., Bian, X., ... Libutti, S. K. (2010). Expression signature developed from a complex series of mouse models accurately predicts human breast cancer survival. Clinical Cancer Research, 16(1), 249-259. https://doi.org/10.1158/1078-0432.CCR-09-1602

Expression signature developed from a complex series of mouse models accurately predicts human breast cancer survival. / He, Mei; Mangiameli, David P.; Kachala, Stefan; Hunter, Kent; Gillespie, John; Bian, Xiaopeng; Shen, H. C Jennifer; Libutti, Steven K.

In: Clinical Cancer Research, Vol. 16, No. 1, 01.01.2010, p. 249-259.

Research output: Contribution to journalArticle

He, M, Mangiameli, DP, Kachala, S, Hunter, K, Gillespie, J, Bian, X, Shen, HCJ & Libutti, SK 2010, 'Expression signature developed from a complex series of mouse models accurately predicts human breast cancer survival', Clinical Cancer Research, vol. 16, no. 1, pp. 249-259. https://doi.org/10.1158/1078-0432.CCR-09-1602
He, Mei ; Mangiameli, David P. ; Kachala, Stefan ; Hunter, Kent ; Gillespie, John ; Bian, Xiaopeng ; Shen, H. C Jennifer ; Libutti, Steven K. / Expression signature developed from a complex series of mouse models accurately predicts human breast cancer survival. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 1. pp. 249-259.
@article{7d481f90970a46c08e660f542c10760b,
title = "Expression signature developed from a complex series of mouse models accurately predicts human breast cancer survival",
abstract = "Purpose: The capability of microarray platform to interrogate thousands of genes has led to the development of molecular diagnostic tools for cancer patients. Although large-scale comparative studies on clinical samples are often limited by the access of human tissues, expression profiling databases of various human cancer types are publicly available for researchers. Given that mouse models have been instrumental to our current understanding of cancer progression, we aimed to test the hypothesis that novel gene signatures possessing predictability in clinical outcome can be derived by coupling genomic analyses in mouse models of cancer with publicly available human cancer data sets. Experimental Design: We established a complex series of syngeneic metastatic animal models using a murine breast cancer cell line. Tumor RNA was hybridized on Affymetrix MouseGenome-430A2.0 Gene-Chips. With the use of Venn logic, gene signatures that represent metastatic competency were derived and tested against publicly available human breast and lung cancer data sets. Results: Survival analyses showed that the spontaneous metastasis gene signature was significantly associated with metastasis-free and overall survival (P < 0.0005). Consequently, the six-gene model was determined and showed statistical predictability in predicting survival in breast cancer patients. In addition, the model was able to stratify poor from good prognosis for lung cancer patients in most data sets analyzed. Conclusions: Together, our data support that novel gene signature derived from mouse models of cancer can be used for predicting human cancer outcome. Our approaches set precedence that similar strategies may be used to decipher novel gene signatures for clinical utility.",
author = "Mei He and Mangiameli, {David P.} and Stefan Kachala and Kent Hunter and John Gillespie and Xiaopeng Bian and Shen, {H. C Jennifer} and Libutti, {Steven K.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1158/1078-0432.CCR-09-1602",
language = "English (US)",
volume = "16",
pages = "249--259",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Expression signature developed from a complex series of mouse models accurately predicts human breast cancer survival

AU - He, Mei

AU - Mangiameli, David P.

AU - Kachala, Stefan

AU - Hunter, Kent

AU - Gillespie, John

AU - Bian, Xiaopeng

AU - Shen, H. C Jennifer

AU - Libutti, Steven K.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Purpose: The capability of microarray platform to interrogate thousands of genes has led to the development of molecular diagnostic tools for cancer patients. Although large-scale comparative studies on clinical samples are often limited by the access of human tissues, expression profiling databases of various human cancer types are publicly available for researchers. Given that mouse models have been instrumental to our current understanding of cancer progression, we aimed to test the hypothesis that novel gene signatures possessing predictability in clinical outcome can be derived by coupling genomic analyses in mouse models of cancer with publicly available human cancer data sets. Experimental Design: We established a complex series of syngeneic metastatic animal models using a murine breast cancer cell line. Tumor RNA was hybridized on Affymetrix MouseGenome-430A2.0 Gene-Chips. With the use of Venn logic, gene signatures that represent metastatic competency were derived and tested against publicly available human breast and lung cancer data sets. Results: Survival analyses showed that the spontaneous metastasis gene signature was significantly associated with metastasis-free and overall survival (P < 0.0005). Consequently, the six-gene model was determined and showed statistical predictability in predicting survival in breast cancer patients. In addition, the model was able to stratify poor from good prognosis for lung cancer patients in most data sets analyzed. Conclusions: Together, our data support that novel gene signature derived from mouse models of cancer can be used for predicting human cancer outcome. Our approaches set precedence that similar strategies may be used to decipher novel gene signatures for clinical utility.

AB - Purpose: The capability of microarray platform to interrogate thousands of genes has led to the development of molecular diagnostic tools for cancer patients. Although large-scale comparative studies on clinical samples are often limited by the access of human tissues, expression profiling databases of various human cancer types are publicly available for researchers. Given that mouse models have been instrumental to our current understanding of cancer progression, we aimed to test the hypothesis that novel gene signatures possessing predictability in clinical outcome can be derived by coupling genomic analyses in mouse models of cancer with publicly available human cancer data sets. Experimental Design: We established a complex series of syngeneic metastatic animal models using a murine breast cancer cell line. Tumor RNA was hybridized on Affymetrix MouseGenome-430A2.0 Gene-Chips. With the use of Venn logic, gene signatures that represent metastatic competency were derived and tested against publicly available human breast and lung cancer data sets. Results: Survival analyses showed that the spontaneous metastasis gene signature was significantly associated with metastasis-free and overall survival (P < 0.0005). Consequently, the six-gene model was determined and showed statistical predictability in predicting survival in breast cancer patients. In addition, the model was able to stratify poor from good prognosis for lung cancer patients in most data sets analyzed. Conclusions: Together, our data support that novel gene signature derived from mouse models of cancer can be used for predicting human cancer outcome. Our approaches set precedence that similar strategies may be used to decipher novel gene signatures for clinical utility.

UR - http://www.scopus.com/inward/record.url?scp=74949109945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74949109945&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-1602

DO - 10.1158/1078-0432.CCR-09-1602

M3 - Article

C2 - 20028755

AN - SCOPUS:74949109945

VL - 16

SP - 249

EP - 259

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -